Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes can and will comply with the requirements of the protocol.~* A male or female between, and including, 18 and 59 years of age at the time of the first vaccination.~* Written informed consent obtained from the subject.~* Female subjects of non-childbearing potential may be enrolled in the study.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has practiced adequate contraception for 30 days prior to vaccination, and~ * has a negative pregnancy test on the day of vaccination, and~ * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.~* Seronegative for HIV- 1 and -2 antibodies.~* No history of or current extrapulmonary tuberculosis TB. Additionally, based on medical history,~* Subjects in the TB-naive cohort must~  * have no active pulmonary disease as indicated by chest X-ray.~ * have no signs and symptoms of TB.~ * have no history of chemoprophylaxis or treatment for TB.~* Subjects in the TB-treated cohort must~  * have a history of successful treatment for pulmonary TB (completed at least 1 year prior to vaccination).~ * have no active pulmonary disease on chest X-ray.~* Subjects in the TB-treatment cohort must - have documented treatment for pulmonary TB (smear- or culture confirmed) ongoing for 2-4 months prior to vaccination.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Administration of a registered live vaccine not foreseen by the study within 30 days preceding the first dose of study vaccine and administration of a registered inactivated vaccine within 14 days preceding the first dose of study vaccine.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Any chronic drug therapy to be continued during the study period, which in the opinion of the investigator could adversely interfere with the vaccine.~* History of previous administration of experimental TB vaccines.~* History of previous exposure to components of the investigational vaccine within 30 days preceding the first dose of study vaccine.~* Administration of any immunoglobulins, any immunotherapy and/or any blood products within the 3 months preceding the first dose of study vaccination, or planned administrations during the study period.~* Planned participation or participation in another experimental protocol during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.~* History of chronic alcohol and/or drug abuse.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Major congenital defects.~* Pregnant female, lactating female or female planning to become pregnant or discontinue contraceptive precautions during the active phase of the study (from study start till 2 months after dose 2).~* Additionally, for the TB naïve and TB treated cohorts:~  - Acute or chronic clinically relevant pulmonary, cardiovascular, hepatic or renal function abnormality as determined by physical examination or laboratory screening tests~* Additionally, for the TB treatment cohort:~  * Acute or chronic clinically relevant pulmonary, cardiovascular, hepatic or renal function abnormality as determined by physical examination or laboratory screening tests. Individuals with grade 3 levels will be excluded.~ * Failure to convert while on anti-TB treatment at the end of the second month of anti-TB therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects from TB-treated cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
- Group B (Type: PLACEBO_COMPARATOR): Subjects from TB-treated cohort will receive 2 doses of physiological Saline.
- Group C (Type: EXPERIMENTAL): Subjects from TB-treatment cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
- Group D (Type: PLACEBO_COMPARATOR): Subjects from TB-treatment cohort will receive 2 doses of physiological Saline.
- Group E (Type: EXPERIMENTAL): Subjects from TB-naive cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
- Group F (Type: PLACEBO_COMPARATOR): Subjects from TB-naive cohort will receive 2 doses of physiological Saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues